Abstract
Abstract Recent studies on the pathomechanism of Alzheimer's disease have shown profound alterations in GABA signaling in brains of dementia patients. GABA is the major inhibitory neurotransmitter in the brain, responsible for controlling other neurotransmitter systems. Deficits in GABAergic transmission may lead to cognitive impairments and to behavioral and psychological symptoms of Alzheimer's dementia. Therefore GABAergic transmissionas may be considered as a viable target for novel anti-dementia drugs. Several projects have been initiated worldwide searching for selective ligands of the GABA-A receptor subunits and multimodal substances acting at different neurotransmitter systems, including the GABA-A receptor. Results of preclinical studies and preliminary data from clinical trials tend to indicate that GABA-A receptor ligands may be potential therapeutic agents for the treatment of Alzheimer's disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
